Testing a new radioactive antibody treatment for children with brain cancer

Plain-English translation of NCT07698899 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called 177Lu-DTPA-omburtamab, which combines a radioactive substance with an antibody (a protein that helps the immune system fight cancer). The antibody is designed to attach to cancer cells in the brain or spinal cord, while the radioactive part delivers treatment directly to those cells. Researchers want to find out if this treatment is safe for children and teenagers whose brain cancer has come back or stopped responding to standard therapies.

Many children with recurrent or treatment-resistant brain cancers have limited options, and their cancers can spread to the brain and spinal cord even after initial treatment. This medication offers a new approach by targeting cancer cells more precisely, which could help patients who have run out of other treatment choices.

Do you qualify?

You likely qualify if…

you are between 3 and 21 years old at the time of enrollment
you have been diagnosed with a tumor that expresses B7-H3 (such as medulloblastoma, neuroblastoma, or certain other brain tumors)
your cancer has come back (recurred) or stopped responding (become refractory) to standard treatments, with disease in your brain or spinal cord
you have recovered from serious side effects of previous cancer treatments, with appropriate time passed since your last chemotherapy, radiation, or other therapy
your neurological symptoms (such as weakness or numbness) are stable, and if you have seizures, they are controlled with medication

You likely don't qualify if…

you have received certain prior cancer treatments too recently (such as chemotherapy within 3 weeks, radiation within 2–3 weeks, or stem cell transplant within 2 months)
you have severe neurological problems that prevent you from being at least 50% active and able to care for yourself
you are pregnant or breastfeeding
you have serious kidney, liver, or heart problems that would make this treatment unsafe
you are currently taking another experimental cancer treatment or investigational medication

What participation looks like

You would receive the radioactive antibody treatment as an injection, likely in the hospital or clinic setting. The trial is testing four different dose levels, starting at the lowest and moving to higher doses only if earlier doses are found to be safe. You would have regular follow-up visits and blood tests to monitor your health and how well the treatment is working. The study plans to enroll about 18 children and adolescents in total.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(7 sites)

United States

Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

Memorial Sloan Kettering at Monmouth (Limited Protocol Activities), Middletown, New Jersey

Memorial Sloan Kettering at Bergen (Limited Protocol Activities), Montvale, New Jersey

Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities), Commack, New York

Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison, New York